Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia

The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic

(2010) L. S. Elias et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effectiveness and safety of colistin: prospective comparative cohort study

(2010) Mical Paul et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Multidrug-resistantPseudomonas aeruginosaandAcinetobacter baumannii: resistance mechanisms and implications for therapy

(2009) Alexandre P Zavascki et al.   Expert Review of Anti-Infective Therapy

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

(2009) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

SCORING SYSTEMS FOR PREDICTION OF MORTALITY IN PATIENTS WITH INTENSIVE CARE UNIT-ACQUIRED SEPSIS

(2009) Ji-Young Rhee et al.   SHOCK

CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting

(2008) Teresa C. Horan et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients

(2008) Alexandre P. Zavascki et al.   CLINICAL INFECTIOUS DISEASES

Nosocomial bloodstream infections due to metallo- -lactamase-producing Pseudomonas aeruginosa

(2008) A. P. Zavascki et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.

(2008) M. S. Oliveira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Intravenous colistimethate for multidrug-resistant Gram-negative bacteria

(2008) Alexandre P Zavascki et al.   LANCET INFECTIOUS DISEASES